Synthekine is pioneering the development of next-generation selective cytokine therapeutics aimed at transforming treatment paradigms for cancer and autoimmune/inflammatory diseases. The company focuses on three innovative cytokine modalities: cytokine partial agonists, orthogonal cytokine and cell therapies, and surrogate cytokine agonists. By engineering cytokines to be selective, Synthekine aims to enhance therapeutic efficacy while minimizing the toxicities often associated with traditional cytokine therapies. For instance, their lead candidate, STK-012, is designed as an α/β-biased IL-2 partial agonist that preferentially stimulates tumor antigen-activated T cells, thereby improving the therapeutic index compared to conventional IL-2 therapies.

In addition to partial agonists, Synthekine's orthogonal cytokine technology allows for the development of cell therapies that can be selectively activated in vivo, independent of the endogenous cytokine system. This is exemplified by their SYNCAR-001 therapy, which combines an engineered CAR-T cell with STK-009, an orthogonal IL-2 ligand, to enhance the efficacy of the treatment while reducing associated toxicities. Furthermore, Synthekine is exploring surrogate cytokine agonists that can create new pharmacological classes of therapeutics by dimerizing or multimerizing receptor subunits in novel ways. This comprehensive approach positions Synthekine at the forefront of cytokine therapeutic innovation, with a robust pipeline targeting various cancers and autoimmune conditions.

United States

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Synthekine

Company Details